Cftr regulators and methods of use thereof

Abstract

Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders, and other diseases and disorders.

What is claimed is: 
     
         1 . A method of treating a dry eye disorder in a subject in need thereof, comprising administering to the subject an effective amount a compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein:
 X is —O—; 
 R 2  is C 2 -C 4  haloalkyl substituted with at least four fluorines, substituted heteroalkyl, or unsubstituted heteroalkyl; 
 R 3  is hydrogen; 
 R 4  is substituted or unsubstituted alkyl; 
 R 5  is hydrogen; and 
 R 1 , R 6 , R 7 , R 8  and R 9  are each hydrogen. 
 
       
     
     
         2 . The method of  claim 1 , wherein R 4  is —CH 3  or —CH 2 CH 3 . 
     
     
         3 . The method of  claim 1 , wherein R 2  is C 2 -C 4  haloalkyl substituted with at least four fluorines. 
     
     
         4 . The method of  claim 3 , wherein R 2  is —CH(CF 3 ) 2  or —CH 2 -CF 2 —CHF 2 . 
     
     
         5 . The method of  claim 1 , wherein the compound of Formula I is: 
       
         
           
           
               
               
           
         
       
     
     
         6 . The method of  claim 5 , wherein the dry eye disorder is a lacrimal gland disorder. 
     
     
         7 . The method of  claim 5 , further comprising administering to the subject an anti-dry eye agent. 
     
     
         8 . A method of increasing lacrimation in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein:
 X is —O—; 
 R 2  is C 2 -C 4  haloalkyl substituted with at least four fluorines, substituted heteroalkyl, or unsubstituted heteroalkyl; 
 R 3  is hydrogen; 
 R 4  is substituted or unsubstituted alkyl; 
 R 5  is hydrogen; and 
 R 1 , R 6 , R 7 , R 8  and R 9  are each hydrogen. 
 
       
     
     
         9 . The method of  claim 8 , wherein R 4  is —CH 3  or —CH 2 CH 3 . 
     
     
         10 . The method of  claim 8 , wherein R 2  is C 2 -C 4  haloalkyl substituted with at least four fluorines. 
     
     
         11 . The method of  claim 10 , wherein R 2  is —CH(CF 3 ) 2  or —CH 2 -CF 2 —CHF 2 . 
     
     
         12 . The method of  claim 8 , wherein the compound of Formula I is: 
       
         
           
           
               
               
           
         
       
     
     
         13 . A method of activating a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), comprising contacting the CFTR with an effective amount of a compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein:
 X is —O—; 
 R 2  is C 2 -C 4  haloalkyl substituted with at least four fluorines, substituted heteroalkyl, or unsubstituted heteroalkyl; 
 R 3  is hydrogen; 
 R 4  is substituted or unsubstituted alkyl; 
 R 5  is hydrogen; and 
 R 1 , R 6 , R 7 , R 8  and R 9  are each hydrogen. 
 
       
     
     
         14 . The method of  claim 13 , wherein R 4  is —CH 3  or —CH 2 CH 3 . 
     
     
         15 . The method of  claim 13 , wherein R 2  is C 2 -C 4  haloalkyl substituted with at least four fluorines. 
     
     
         16 . The method of  claim 15 , wherein R 2  is —CH(CF 3 ) 2  or —CH 2 -CF 2 —CHF 2 . 
     
     
         17 . The method of  claim 13 , wherein the compound of Formula I is: